biote Corp. (BTMD)
NASDAQ: BTMD · Real-Time Price · USD
3.470
-0.010 (-0.29%)
Apr 23, 2025, 4:00 PM EDT - Market closed

Company Description

biote Corp. operates in practice-building business within the hormone optimization space.

It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance.

The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.

It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female.

The company was founded in 2012 and is headquartered in Irving, Texas.

biote Corp.
biote logo
Country United States
Founded 2012
Industry Medical Care Facilities
Sector Healthcare
Employees 217
CEO Bret Christensen

Contact Details

Address:
1875 W. Walnut Hill Ln #100
Irving, Texas 75038
United States
Phone 844 604 1246
Website biote.com

Stock Details

Ticker Symbol BTMD
Exchange NASDAQ
Stock Type Common Stock
Share Class Class A Shares
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001819253
CUSIP Number 090683103
ISIN Number US0906831039
Employer ID 85-1791125
SIC Code 2833

Key Executives

Name Position
Bret Christensen Chief Executive Officer and Director
Marc D. Beer Executive Chairman
Robert C. Peterson Chief Financial Officer
John J. Olsen Chief Information Officer
Mary Elizabeth Conlon Vice President of Business Development, General Counsel and Corporate Secretary
Joel Pickering Chief Marketing Officer
James Elliott Gibbs II Chief People Officer
Richard Kevin Key Chief Digital Officer
Jade Beutler Head of Nutraceuticals
Dr. Cory Rice D.O. Chief Clinical Advisor and Member of Medical Advisory Board

Latest SEC Filings

Date Type Title
Apr 11, 2025 EFFECT Notice of Effectiveness
Apr 9, 2025 POS AM Post-Effective amendments for registration statement
Apr 9, 2025 S-8 Securities to be offered to employees in employee benefit plans
Apr 3, 2025 ARS Filing
Apr 3, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 3, 2025 DEF 14A Other definitive proxy statements
Mar 18, 2025 SCHEDULE 13G/A Filing
Mar 17, 2025 8-K Current Report
Mar 14, 2025 10-K Annual Report
Mar 12, 2025 8-K Current Report